Methodist Physicians Clinic
Omaha, Nebraska, 68114, United States
Location status: Recruiting
NCT Number: NCT07554352
The goal of this observational study is to evaluate the safety and effectiveness of a home-monitoring device (RespirAI) in the early detection of COPD exacerbations in adults (age >21) with physician-diagnosed COPD who are at high risk for exacerbations. The study will collect data from participants with COPD that will be analyzed using an AI-based algorithm to predict exacerbation events. The device's predictions will then be compared against clinically documented exacerbations to assess detection accuracy.
Interested in participating?
Request Info21 year and older
All sexes
Observational
Omaha, Nebraska, 68114, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Use of a software-based monitoring device for 6 months.
Time frame: 6 months
Percentage of clinically verified moderate or severe COPD exacerbation events detected by the device
Time frame: 6 months
The rate of false alarms produced by the device.
Interested in participating?
Request InfoRespirAI US Inc
Industry
A Multi-center, Observational Prospective Clinical Study to Evaluate the Safety and Effectiveness of a Home - Monitoring COPD Management Software for Early Detection of Exacerbations.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04860375
COPD, COPD Exacerbation
Gothenburg, VGR, Sweden
View Trial DetailsNCT05825014
COPD Exacerbation
Hong Kong, New Territories
View Trial DetailsNCT07302425
COPD Exacerbation, Chronic Disease
Lumezzane, Brescia, Italy
View Trial DetailsNCT05829083
COPD, COPD Exacerbation
Athens, Greece
View Trial Details